Back to News
Feb 13, 2026 8:30 AM

Sanofi Stock Near 52-Week Low As Leadership Shakeup Rattles Investors

Sanofi SA (NASDAQ:SNY) shares are down during Friday’s premarket session as the company faces leadership changes amid ongoing challenges in its drug pipeline.

On Thursday, the French drugmaker with a market cap of around $113.6 billion closed 4.5% lower, closer to the lower end of the 52-week range of $44.62-$60.12.

The stock’s decline comes as the board announced the departure of CEO Paul Hudson, who will be succeeded by Belén Garijo, adding pressure as broader markets edged lower.

Sanofi CEO Transition Amid Pipeline Challenges

On Thursday, Sanofi’s board decided not to renew Paul Hudson’s mandate, with his last day as CEO set for February 17.

Belén Garijo will take over after the Group’s Annual General Meeting on April 29, as the company aims to enhance its strategy and innovation capacity, particularly in Research & Development.

In the fourth quarter of 2025, Sanofi reported a 32.2% increase in sales of its top drug, Dupixent, totaling 4.2 billion euros.

However, the ...